Danaher (NYSE:DHR – Get Free Report) issued its quarterly earnings results on Tuesday. The conglomerate reported $1.71 EPS for the quarter, beating analysts’ consensus estimates of $1.57 by $0.14, Briefing.com reports. Danaher had a net margin of 16.94% and a return on equity of 11.06%. The business had revenue of $5.80 billion for the quarter, compared to analysts’ expectations of $5.59 billion. During the same quarter in the prior year, the firm posted $2.02 earnings per share. The business’s quarterly revenue was up 3.1% compared to the same quarter last year.
Danaher Stock Performance
NYSE DHR opened at $255.35 on Thursday. The company has a fifty day moving average price of $270.43 and a 200-day moving average price of $260.43. The firm has a market cap of $189.13 billion, a price-to-earnings ratio of 43.39, a PEG ratio of 4.49 and a beta of 0.83. The company has a debt-to-equity ratio of 0.33, a current ratio of 1.43 and a quick ratio of 1.04. Danaher has a 1 year low of $182.09 and a 1 year high of $281.70.
Danaher Dividend Announcement
The business also recently disclosed a quarterly dividend, which will be paid on Friday, October 25th. Shareholders of record on Friday, September 27th will be paid a dividend of $0.27 per share. This represents a $1.08 annualized dividend and a yield of 0.42%. The ex-dividend date of this dividend is Friday, September 27th. Danaher’s dividend payout ratio (DPR) is presently 18.31%.
Insider Activity at Danaher
Analysts Set New Price Targets
Several brokerages recently commented on DHR. KeyCorp upped their target price on Danaher from $290.00 to $310.00 and gave the company an “overweight” rating in a research report on Wednesday. Barclays reduced their price objective on shares of Danaher from $285.00 to $275.00 and set an “equal weight” rating for the company in a research report on Wednesday. The Goldman Sachs Group boosted their target price on shares of Danaher from $225.00 to $250.00 and gave the company a “neutral” rating in a research report on Wednesday, July 24th. Royal Bank of Canada reduced their price target on shares of Danaher from $333.00 to $311.00 and set an “outperform” rating for the company in a report on Wednesday. Finally, TD Cowen upped their price objective on shares of Danaher from $310.00 to $315.00 and gave the company a “buy” rating in a report on Wednesday. Seven research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company. According to MarketBeat.com, Danaher presently has an average rating of “Moderate Buy” and an average price target of $287.28.
View Our Latest Stock Report on Danaher
Danaher Company Profile
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.
Recommended Stories
- Five stocks we like better than Danaher
- What Are Dividend Challengers?
- A $1.75 Billion Gamble: Can Lucid Ignite Growth?
- What does consumer price index measure?
- The Rally in Lockheed Martin and RTX Can Continue: Here’s Why
- 3 Ways To Invest In Coffee, Other Than Drinking It
- 3 Undervalued Technology Stocks With Big Rebound Potential
Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.